DNTH · Dianthus Therapeutics, Inc.
$76.78
-2.23% last session
End-of-day data · close of 2026-10-23
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-16.7
Dividend yield
0.0%
Beta
0.18
Avg volume
1M
Employees
0K
Daily Change %
-2.23%
5 Days Change
8.93%
10 Days Change
1.22%
30 Days Change
-15.96%
60 Days Change
-28.65%
Month to Day Change
-11.08%
Year to Day Change
90.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DNTH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
JP Morgan
Overweight$135
+75.8% vs priceCitigroup
Buy$156
+103.2% vs priceWells Fargo
Overweight$135
+75.8% vs priceJefferies
Buy$81.00
+5.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterates | Buy | $158 |
| 2026-09-11 | JP Morgan | Initiates | Overweight | $0.00 → $135 |
| 2026-09-04 | Citigroup | Initiates | Buy | $0.00 → $156 |
| 2026-08-06 | Truist Securities | Maintains | Buy | $110 → $128 |
| 2026-08-06 | HC Wainwright & Co. | Maintains | Buy | $130 → $158 |
| 2026-08-05 | Wedbush | Maintains | Outperform | $105 → $122 |
| 2026-08-03 | Evercore ISI Group | Maintains | Outperform | $120 → $134 |
| 2026-05-06 | Wedbush | Maintains | Outperform | $103 → $105 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 20.1% below the 50-day MA ($96.03).
- bearish: Price vs 200-day MA: Trading 8.6% below the 200-day MA ($84.03).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.48) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($32.92) and high ($115.96).
DNTH Price Chart
Loading chart for DNTH…
Fundamentals
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.